LOS GATOS, CA – February 11, 2014 – Annai Systems Inc., a genomic data management solution provider, today announced that David Szekeres has joined the company’s Board of Directors.
Mr. Szekeres was recently named Chief Business Officer and General Counsel at Regulus Therapeutics after having served as Deputy General Counsel, Chief M&A Counsel and Assistant Secretary at Life Technologies Corporation (recently sold to Thermo Fisher). At Life Technologies Mr. Szekeres led more than fifty transactions valued at over $30 billion, including leading the acquisition of Ion Torrent to expand Life’s genomics business. He was also responsible for all legal functions in the areas of corporate transactions, corporate governance, SEC reporting and compliance. Prior to his years at Life, Mr. Szekeres held positions of increasing responsibility at a number of prestigious law firms, including Latham & Watkins LLP, O’Melveny & Myers LLP and Dechert LLP. Mr. Szekeres began his career in the investment banking group at Robertson Stephens. Mr. Szekeres also serves on the boards of directors of Anochi BioPharma and the San Diego chapter of the Association of Corporate Counsel. Mr. Szekeres holds a B.A. from the University of California at Irvine and a J.D. from Duke University.
“We are delighted to welcome David to the Annai Systems Board and are excited to be working with this strategic business leader to deliver on Annai’s goals and contribute to the advancement of genomic medicine,” said Michael Penley, Annai Systems’ Chief Executive Officer. “The experience that David brings to our Board will be invaluable as we continue to evolve our strategies and execute on achieving our goals, as the application of genomic data to personalized medicine continues to progress at an explosive pace.”
About Annai Systems
Annai Systems is a leading genomic data analysis company committed to developing cost-reducing innovations the accelerate scientific discovery, maximize statistical power, and optimize data control. From data compression and storage to secondary and tertiary analysis, Annai Systems offers a true end-to-end solution designed to handle the complex needs of next-generation sequencing data in the clinical, pharmaceutical and research environments. The company’s flagship product, STARPlatform, enables researchers to innovate, collaborate, and make new discoveries – all in less time and at lower costs than traditional solutions. For more about Annai Systems, visit www.annaisystems.com.